1. Safety, Tolerability, and Effects of a Single Subcutaneous Administration of SP16 – a SERPIN-like, Small Peptide Agonist of the Low-Density Lipoprotein–like Receptor 1– on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction. Issue 5 (November 2022) Authors: Van Tassell, Benjamin W.; Wohlford, George F.; Del Buono, Marco Giuseppe; Damonte, Juan Ignacio; Markley, Roshanak; Turlington, Jeremy; Kadariya, Dinesh; Talasaz, Azita; Ho, Jane; Marawan, Amr; Thomas, Georgia K.; Austin, Dana; Gineste, Cyrille; Gelber, Cohava; Abbate, Antonio Journal: Journal of cardiovascular pharmacology Issue: Volume 80:Issue 5(2022) Page Start: 672 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?. (November 2007) Authors: Hughes, Peyton; Marshall, Damian; Reid, Yvonne; Parkes, Helen; Gelber, Cohava Journal: Biotechniques Issue: Volume 43:Number 5(2007) Page Start: 575 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Α1‐Antitrypsin derived SP16 peptide demonstrates efficacy in rodent models of acute and neuropathic pain. Issue 1 (9th December 2021) Authors: Wang, Zixuan; Martellucci, Stefano; Van Enoo, Alicia; Austin, Dana; Gelber, Cohava; Campana, Wendy M. Journal: FASEB journal Issue: Volume 36:Issue 1(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗